Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacarbazine in relapsed/refractory MGMT-deficient AML
2014-001303-52Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacarbazine in acute myeloid leukemia (AML), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: Rate of complete remission (CR+CRi) after induction therapy. Started Apr 2014; status: terminated.
02
Drugs
dacarbazine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-001303-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001303-52.